证券代码：300347 证券简称：泰格医药 公告编码（2025）024 号 杭州泰格医药科技股份有限公司 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者 重大遗漏负连带责任。 杭州泰格医药科技股份有限公司（以下简称"公司"）第五届董事会第十六次会议于 2025年4月30日在杭州市滨江区聚工路19号8幢19层会议室举行，本次会议以现场与通讯表 决相结合的方式召开。全体董事一致同意豁免本次董事会会议的提前通知期限，会议通知 已于2025年4月29日以电话、电子邮件方式向全体董事发出。会议应到董事7人，实到董事 7人，本次会议由公司董事长叶小平主持。本次会议的召开及程序符合有关法律、法规和公 司章程的要求，会议合法有效。 经与会董事审议，本次会议以投票表决的方式审议通过如下决议： 一、审议并通过《关于制定<市值管理制度>的议案》。 为加强公司市值管理工作，进一步规范市值管理行为，维护公司、投资者及其他利 益相关者的合法权益，根据《上市公司监管指引第10号——市值管理》等有关法律法规 及规范性文件的规定，公司结合自身实际情况，制定了《市值管理制度》。 表决结果：同意7票，反对0票 ...

证券代码：300347 证券简称：泰格医药 公告编码（2025）023 号 杭州泰格医药科技股份有限公司 关于回购公司股份期限届满暨股份变动的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者 重大遗漏负连带责任。 杭州泰格医药科技股份有限公司（以下简称"公司"）分别于 2024 年 2 月 6 日、2024 年 4 月 12 日及 2024 年 4 月 30 日召开的第五届董事会第四次会议、第五届董事会第七次 会议、2024 年第二次临时股东大会、2024 年第一次A 股类别股东会议以及2024 年第一次 H 股类别股东会议审议通过了《关于回购公司股份方案的议案》及《关于调整回购公司股 份方案的议案》。根据股份回购方案，公司计划以自有资金或自筹资金以集中竞价交易或其 他法律法规允许的方式回购部分公司A 股股份，用于后续实施股权激励或员工持股及注销 减少注册资本。本次回购股份的资金总额将不低于人民币 50,000 万元，且不超过人民币 100,000 万元；回购价格不超过72 元/股。具体回购资金金额以回购实施完成时实际回购的 金额为准。本次回购股份实施期限为自股东大会 ...

• 泰格医药 2025 年一季度营收结构分化，CROS 板块增长，CTS 板块因订 单减少和单价下滑而下降，整体毛利率 30.03%，同比下降但环比改善， 主要受 CTS 板块影响，CROS 板块毛利率保持稳定。 • 公司一季度经营性现金流 1.98 亿元，同比增长 37.4%，应收账款显著减 少，预计全年经营性现金流净额超 10 亿元，现金流管理能力增强，为业 务发展提供保障。 • 一季度净新增订单突破 20 亿元，同比增长约 20%，得益于公司战略调整 和 BD 团队的努力，国内客户订单明显复苏，价格相对稳定，期待下半年 价格复苏。 • 公司持续投入数字化与智能化战略，产生相关费用，但管理费用基本保持 稳定。大额存单利息计入投资收益，对财务费用影响减小，下半年口径将 完全可比。 • 公司注重管理费用控制，特别是子公司方达，同时公允价值变动产生亏损， 主要因基金份额估值下降，但项目融资成功表明一级市场流动性有所恢复。 • 国内创新药政策呵护和资本市场估值回归，促成国内客户订单复苏，预计 未来 2-4 个季度持续。海外客户订单表现良好，但增速不及国内。 • 临床 CRO 供给端改善，中小型 CRO 公司收缩， ...

证券代码：300347 证券简称：泰格医药 公告编码（2025）022 号 杭州泰格医药科技股份有限公司 关于召开 2024 年度股东会、2025 年第一次 A 股类别股东会议及 2025 年第一次 H 股类别股东会议的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者 重大遗漏负连带责任。 一、召开会议的基本情况 1．股东会届次：2024年度股东会、2025年第一次A股类别股东会议及2025年第一次H 股类别股东会议。 2．股东会的召集人：公司董事会。 3．会议召开的合法、合规性：经公司第五届董事会第十四次会议审议通过，决定召开 2024年度股东会、2025年第一次A股类别股东会议及2025年第一次H股类别股东会议，召集 程序符合有关法律、行政法规、部门规章、规范性文件和公司章程的规定。 4．会议召开的日期、时间： 现场会议召开日期和时间：2025 年5 月30 日（星期五）上午10:00 网络投票日期和时间： （1）通过深圳证券交易所交易系统进行网络投票的时间为：2025 年 5 月 30 日上午 9:15—9:25，9:30—11:30 和下午13:00-15:0 ...

Financial Performance - In 2024, the company achieved a revenue of RMB 6.603 billion, with clinical trial technical services contributing RMB 3.178 billion and related laboratory services generating RMB 3.425 billion[12]. - Total revenue for 2024 was RMB 6,603.1 million, a decrease of 10.6% compared to RMB 7,384.0 million in 2023[16]. - Gross profit for 2024 was RMB 2,242.0 million, down 21.3% from RMB 2,848.5 million in 2023[16]. - Net profit attributable to the company's owners for 2024 was RMB 405.1 million, representing an 80.0% decline from RMB 2,024.8 million in 2023[16]. - The company's gross margin decreased to 34.0% in 2024 from 38.6% in 2023, a drop of 4.6 percentage points[16]. - Cash and cash equivalents decreased significantly by 72.3% to RMB 2,048.5 million from RMB 7,399.9 million in 2023[16]. - The company's profit for the reporting period decreased by 79.2% to RMB 447.8 million from RMB 2,149.9 million in the same period last year[75]. - Profit attributable to the company's owners fell by 80.0% to RMB 405.1 million from RMB 2,024.8 million year-on-year[75]. - The net profit margin attributable to the company's owners, excluding non-recurring gains and losses, declined from 20.0% to 12.9%[79]. Market Position and Growth - The net new contract amount for the year reached RMB 8.423 billion, representing a year-on-year growth of 7.3%, while the total backlog of contracts stood at RMB 15.776 billion, up 12.0% year-on-year[12]. - The company maintained a 12.8% market share in China's clinical outsourcing services market, having provided services for over 60% of China's listed Class I new drugs since its establishment[11]. - The total number of clinical trials serviced in 2024 included 28 listed Class I new drugs and 6 innovative medical device projects, reflecting high client recognition of the company's comprehensive service capabilities[12]. - The number of new customers developed by the company increased by 22% year-on-year, enhancing its business cooperation with a diverse client base[25]. - The company continues to maintain a leading position in the Chinese clinical research outsourcing market despite competitive pressures[24]. Operational Developments - The North American clinical operations team expanded to over 120 personnel, covering 25 states and 65 cities, collaborating with over 700 clinical centers and 100 oncology centers[13]. - The company completed the acquisition of Medical Edge in Japan and reported strong performance in South Korea, enhancing its regional capabilities[13]. - The company established a Clinical Operations Strategy Committee to enhance clinical strategy capabilities and improve project bidding success rates[26]. - The company formed targeted business development teams in specific therapeutic areas, including Cell and Gene Therapy (CGT), Radiopharmaceuticals, Weight Loss, Ophthalmology, and Central Nervous System (CNS) diseases[26]. - The company expanded its overseas business, achieving rapid growth in new orders, revenue, and profits in its international clinical CRO business in 2024[27]. Innovation and Technology - 23% of clinical trials adopted a decentralized clinical trial (DCT) hybrid model, significantly improving participant engagement and project execution flexibility[13]. - The company launched multiple remote intelligent platforms, including the CTRM remote monitoring system and the Safety Portal for safety reporting, to enhance clinical research efficiency[13]. - The company has established a digital advancement center to drive the implementation of its digital and intelligent strategies, which is now taking shape[38]. - The AI-driven medical translation business has developed a full-chain AI translation product capability, improving efficiency and accuracy in medical document translation[39]. - The application of AI technology in clinical trials is expected to improve efficiency and reduce costs, leading to innovations in existing service models[132]. Regulatory Environment and Industry Trends - The clinical research outsourcing industry in China is expected to grow at an average annual rate of 12.6% from 2024 to 2028, reaching an estimated market size of approximately RMB 75 billion by 2028[19]. - In 2024, the National Medical Products Administration approved 48 Class I innovative drugs, an increase of 8 compared to 2023, marking a historical high[20]. - The Chinese government has introduced comprehensive support policies for innovative drug development, including a plan to complete clinical trial reviews within 30 working days[22]. - The competitive landscape in the clinical CRO industry is evolving, with smaller firms beginning to scale back, while demand for CRO services is recovering as the domestic biopharmaceutical industry stabilizes[132]. - The Chinese government is actively promoting high-quality development in the biopharmaceutical industry through various policies, including financial support and optimizing review processes for innovative drug development[134]. Financial Management and Investments - Cash used in investing activities increased by 208.9% to RMB 4,739.1 million from RMB 1,534.2 million year-on-year, primarily due to cash payments for acquisitions[83]. - The company plans to utilize funds for expanding clinical trial technology services, repaying bank loans, and general corporate purposes to enhance financial management flexibility[128]. - The company plans to continue selective acquisitions and investments for growth, but failure to identify suitable targets or successfully implement these transactions could adversely affect financial performance[148]. - The company has announced the acquisition of NAMSA's China business, expanding its team and overseas service reach[48]. Risks and Challenges - The company faces potential risks from natural disasters, pandemics, and other emergencies that could adversely affect its operations, financial condition, and performance[139]. - A decline in demand for biopharmaceutical research and development services could significantly impact the company's business, financial condition, and performance[140]. - Increased competition in the global pharmaceutical contract research market poses risks related to pricing, service quality, and client relationships, which could affect the company's revenue and profitability[142]. - The company acknowledges the risk of talent loss among directors and senior management, which could disrupt business operations and growth plans[150]. Corporate Governance and Management - The board consists of seven members, including four executive directors and three independent non-executive directors[159]. - The company is committed to maintaining high standards of corporate governance through its independent directors and various committees[168]. - The management team has a strong educational background, with degrees from prestigious institutions such as Oxford University and Zhejiang University, enhancing their strategic capabilities[164][167]. - The company has established mechanisms to ensure independent opinions and advice are available to the board[197]. - The company has complied with the corporate governance code during the reporting period[189].

美团-W(03690)早盘涨3.82%，机构预计外卖行业竞争格局将保持稳定，平台价值有望长期释放。 智通财经APP获悉，港股恒生指数涨0.12%，涨26点，报21998点；恒生科技指数涨0.81%；港股早盘成 交973亿港元。 蚂蚁拟斥资28.14亿港元收购耀才证券控股权，阿里系板块全线走高。耀才证券金融(01428)再涨20%； 阿里健康（00241）涨6%。 上美股份(02145)涨8%，股价续刷历史新高，机构看好美护板块优质标的长期成长性。 泰格医药(03347)绩后跌超2%，一季度归母净利同比减少近三成，机构指其毛利率水平仍有提升空间。 青岛啤酒股份(00168)绩后跌3.7%，一季度净利润同比增长7.08%。 长江生命科技(00775)再涨超9%，公司在AACR 2025展示多种癌症疫苗数据。 龙源电力(00916)绩后跌超6%，一季度归母净利同比减少21.82%，风电分部收入同比减少1.89%。 荣昌生物(09995)绩后跌8.21%，一季度营收同比增近六成，亏损收窄至2.54亿元。 地平线机器人-W(09660)涨超9%，近日与电装达成战略合作，机构指产业链景气度确定性上行。 赤子城科技(099 ...

证券代码：300347 证券简称：泰格医药 公告编码（2025）021 号 杭州泰格医药科技股份有限公司 第五届董事会第十五次会议决议公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者重 大遗漏负连带责任。 杭州泰格医药科技股份有限公司（以下简称"公司"）第五届董事会第十五次会议于 2025年4月28日在杭州市滨江区聚工路19号盛大科技园A座19层会议室举行，本次会议以现 场与通讯表决相结合的方式召开。会议通知已于2025年4月14日以电话、电子邮件方式向全 体董事发出。会议应到董事7人，实到董事7人，本次会议由公司董事长叶小平主持。本次 会议的召开及程序符合有关法律、法规和公司章程的要求，会议合法有效。 一、 审议并通过《关于公司2025年第一季度报告的议案》。 具体内容详见中国证监会创业板指定信息披露网站同期披露的《公司2025年第一季度 报告全文》。 表决结果：同意7票，反对0票，弃权0票。 特此公告。 杭州泰格医药科技股份有限公司董事会 二〇二五年四月二十九日 1 经与会董事审议，本次会议以投票表决的方式审议通过如下决议： ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,564,143,614.71, a decrease of 5.79% compared to CNY 1,660,204,321.44 in the same period last year[5] - Net profit attributable to shareholders was CNY 165,468,741.43, down 29.61% from CNY 235,072,002.70 year-on-year[5] - The net profit after deducting non-recurring gains and losses was CNY 102,328,863.87, a significant decline of 66.23% compared to CNY 303,052,196.14 in the previous year[5] - Total operating revenue for the current period was ¥1,564,143,614.71, a decrease of 5.79% from ¥1,660,204,321.44 in the previous period[22] - Net profit for the current period was ¥109,980,847.86, down 64.80% from ¥312,570,373.39 in the previous period[23] - Earnings per share decreased to ¥0.19 from ¥0.27 in the previous period[23] Cash Flow - The company reported a net cash flow from operating activities of CNY 197,934,614.18, an increase of 37.26% from CNY 144,204,460.07 in the same period last year[5] - Cash generated from operating activities increased to ¥1,630,273,549.06, compared to ¥1,476,940,313.67 in the previous period[25] - The net cash flow from operating activities was $197.93 million, an increase of 37.4% compared to $144.20 million in the previous period[26] - Total cash inflow from operating activities amounted to $1.65 billion, up from $1.55 billion year-over-year[26] - Cash outflow from investing activities resulted in a net cash flow of -$657.87 million, worsening from -$119.72 million in the previous period[26] - Cash inflow from financing activities totaled $617.96 million, compared to $447.50 million in the prior year, reflecting a 38.1% increase[26] - The net cash flow from financing activities was -$103.87 million, a decline from a positive $2.42 million in the previous period[26] - The ending cash and cash equivalents balance was $1.49 billion, down from $7.42 billion at the end of the previous period[26] Assets and Liabilities - The total assets at the end of the reporting period were CNY 28,729,592,949.22, reflecting a slight increase of 0.20% from CNY 28,671,015,787.16 at the end of the previous year[5] - The company reported a total current assets of ¥5,895,369,481.10, down from ¥6,299,685,225.86 at the beginning of the period[18] - The total amount of accounts receivable is ¥1,155,388,839.63, decreased from ¥1,359,758,181.20[18] - Total liabilities increased to ¥4,820,982,910.72 from ¥4,606,536,600.57 in the previous period[20] - The company's total equity decreased to ¥23,908,610,038.50 from ¥24,064,479,186.59 in the previous period[20] Investments and Shareholder Information - The company signed new contracts worth over CNY 2 billion in Q1 2025, representing a year-on-year growth rate of 20%[11] - The company experienced a 127.11% increase in trading financial assets, totaling CNY 170,000,000.00, primarily due to the purchase of wealth management products[8] - The company’s long-term equity investments increased to ¥3,911,115,451.09 from ¥3,424,603,314.72[18] - The largest shareholder, Ye Xiaoping, holds 20.49% of shares, totaling 177,239,541 shares[13] - Total number of common shareholders at the end of the reporting period is 53,774[13] - The total number of shares held by the top ten unrestricted shareholders is 123,118,879 shares[14] - The company has a total of 171,687,044 shares under lock-up agreements, with no shares released during the period[16] Borrowings and Financial Expenses - Long-term borrowings rose by 79.72% to CNY 581,674,789.07, attributed to new long-term loans obtained during the reporting period[8] - The company reported a significant increase in financial expenses, amounting to CNY 31,748,445.86, due to reduced foreign exchange gains and the reclassification of interest from large time deposits[9] - Long-term borrowings rose significantly to ¥581,674,789.07 from ¥323,649,635.25 in the previous period[20] Strategic Planning - The company plans to continue investing in digital and intelligent technology development as part of its strategic planning[11] Other Financial Metrics - The company reported an investment income of ¥25,309,680.34, compared to a loss of ¥3,591,151.18 in the previous period[22] - Cash inflow from investment activities was $148.93 million, a decrease from $162.65 million year-over-year[26] - Cash outflow for purchasing fixed assets and other long-term assets was $48.09 million, significantly lower than $111.54 million in the previous period[26] - The company received $62.60 million from investment, compared to $21.30 million in the prior year, indicating strong investor interest[26] - The company reported a cash inflow of $555.36 million from borrowings, an increase from $373.01 million in the previous period[26]

Financial Performance - The company's operating revenue for Q1 2025 was RMB 1,564,143,614.71, a decrease of 5.79% compared to RMB 1,660,204,321.44 in the same period last year[12]. - Net profit attributable to shareholders was RMB 165,468,741.43, down 29.61% from RMB 235,072,002.70 year-on-year[12]. - The net profit after deducting non-recurring gains and losses was RMB 102,328,863.87, a significant decline of 66.23% from RMB 303,052,196.14 in the previous year[12]. - Operating profit decreased to CNY 144,504,382.40, down 60.0% from CNY 362,196,228.41 in the previous period[43]. - Net profit for the current period is CNY 109,980,847.86, a decline of 64.8% compared to CNY 312,570,373.39 in the previous period[43]. - The company reported a total comprehensive income of CNY 115,310,625.21, down 60.3% from CNY 290,331,159.48 in the previous period[44]. Cash Flow - The net cash flow from operating activities increased by 37.26% to RMB 197,934,614.18, compared to RMB 144,204,460.07 in the same period last year[12]. - The company reported a significant increase in investment cash outflows, which rose by 449.52% to RMB -657,869,238.36, mainly due to increased investments in joint ventures[23]. - Cash inflow from sales of goods and services reached ¥1,630,273,549.06, an increase of 10.3% from ¥1,476,940,313.67[47]. - Total cash outflow from operating activities was ¥1,454,545,978.13, an increase of 3.5% compared to ¥1,405,522,357.29 in the previous period[47]. - Cash inflow from financing activities amounted to ¥617,956,000.00, up 38.1% from ¥447,503,471.27 in the last period[48]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 28,729,592,949.22, reflecting a slight increase of 0.20% from RMB 28,671,015,787.16 at the end of the previous year[14]. - Total liabilities increased to CNY 4,820,982,910.72 from CNY 4,606,536,600.57, reflecting a growth of 4.6%[42]. - Long-term borrowings rose by 79.72% to RMB 581,674,789.07, attributed to new long-term loans obtained during the reporting period[19]. - The total current assets decreased from 6,299,685,225.86 RMB to 5,895,369,481.10 RMB, reflecting a decline of about 6.4%[36]. - The total liabilities decreased from 3,661,852,465.12 RMB to 3,635,724,221.91 RMB, showing a decline of approximately 0.7%[38]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 53,774[26]. - The top shareholder, Ye Xiaoping, holds a 20.49% stake, amounting to 177,239,541 shares[27]. - The company has a total of 171,687,044.00 shares under lock-up, with a release schedule of 25% per year for executives[33]. Other Financial Metrics - The weighted average return on net assets was 0.80%, down from 1.12% in the previous year, a decrease of 0.32%[12]. - The company’s income tax expense decreased by 32.43% to RMB 33,644,494.98, primarily due to a decline in pre-tax profits[22]. - The company incurred a 679.32% increase in non-operating expenses, amounting to RMB 1,038,576.02, largely due to increased donation expenditures[22]. - Earnings per share (EPS) for the current period is CNY 0.19, down from CNY 0.27 in the previous period[44]. - Other comprehensive income after tax for the current period is CNY 5,329,777.35, compared to a loss of CNY 22,239,213.91 in the previous period[43].

智通财经APP获悉，国投证券发布研报称，根据Crunchbase的数据，2024年全球和美国创新药VC&PE投 融资金额分别同比增长1.93%和5.29%，2024年全球和美国创新药VC&PE投融资情况已恢复正增长，创 新药投融资环境已逐步改善；热门赛道研发方面，多肽、ADC等领域研发需求旺盛，推动相关领域研 发外包需求提升。目前CXO上市公司相关订单开始逐步改善且产能处于行业领先地位，看好CXO上市 公司业绩边际改善，其中，在订单方面，药明康德、药明合联、凯莱英、康龙化成、博腾股份等多家上 市公司新签/在手订单已及时回暖。 国投证券主要观点如下： 宏观维度：全球创新药投融资持续改善，研发需求复苏可期 根据Frost& Sullivan的数据，预计全球肽类药物的研发生产服务外包的市场规模从2025年的47亿美元增 长至2032年188亿美元，全球ADC药物的研发生产服务外包的市场规模有望从2022年的15亿美元增长至 2030年的110亿美元。 微观维度：新签订单及时回暖，看好2025年CXO业绩改善 目前CXO上市公司相关订单开始逐步改善且产能处于行业领先地位，看好CXO上市公司业绩边际改 善。其中，订单方 ...